GSK AND TANABE TO COLLABORATE ON DEVELOPMENT AND COMMERCIALISATI

GSK and Tanabe To Collaborate On Development and Commercialisation Of Preclinical Products Tanabe Seiyaku Co, Ltd. and GlaxoSmithKline plc (GSK) today announce that they have signed a letter of intent to enter into a broad-ranging global collaboration on the research, development and commercialisation of a series of compounds from Tanabe, which covers a range of potential therapeutic areas, including psychiatry, neurology, urology and diabetes. The terms of the Agreement remain to be finalised, but under the letter of intent, GSK will gain access to pre-clinical compounds, with the possibility of bringing additional new Tanabe compounds within the scope of the collaboration at a later date. This world-wide collaboration will allow Tanabe and GSK to share commercialisation rights in specific territories. GSK and Tanabe will form an Executive Steering Committee to oversee the research, development and marketing of the compounds. "This collaboration with GlaxoSmithKline will promote our effort to revitalize our research organization, to maximize the efficiency of drug discovery process and to speed up the R&D operations in developing innovative products" said Mr. Shoei Nakashima, Senior Managing Director, Tanabe Seiyaku Co., Ltd. "This agreement is another example of excellent synergy between GSK's expertise in research, development and commercialisation with that of Tanabe's strong scientific endeavours, so that together we can maximise the worldwide potential of promising new compounds", said Dr. Tadataka Yamada, Chairman, Research & Development, GlaxoSmithKline. GlaxoSmithKline-one of the world's leading research-based pharmaceutical and healthcare companies-is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com. Tanabe Seiyaku Co., Ltd.- a Japan based pharmaceutical company with the tradition that goes back as far as 1678 - has a management philosophy to contribute to the health and comfort of people around the world by providing its superior pharmaceutical products. For company information, visit Tanabe Seiyaku on the World Wide Web at http://www.tanabe.co.jp/english/index.html. Enquiries: GlaxoSmithKline Martin Sutton (020) 8966 8372 UK Media enquiries Philip Thomson (020) 8966 8372 Alan Chandler (020) 8966 8372 US Media enquiries Nancy Pekarek (215) 751 7709 Mary Anne (919) 483 2839 Rhyne European Analyst/Investor Jennie Younger (020) 8966 8378 enquiries Duncan (020) 8966 5961 Learmouth Anita Kidgell (020) 8966 8369 US Analyst/Investor Frank Murdolo (215) 751 7002 enquiries Tom Curry (215) 751 5419 Tanabe Seiyaku Co. Ltd Corporate Communications Division Osaka Tel: +81 6 6205 5211 Fax: +81 6 6205 5105 Tokyo Tel: +81 3 3230 6757 Fax: +81 3 3230 6888 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/09/11/20010911BIT00250/bit0001.doc http://www.waymaker.net/bitonline/2001/09/11/20010911BIT00250/bit0001.pdf